Product Description
A drug used to prevent blood clots from forming or to treat blood clots that have formed in patients with cancer or other conditions. Dalteparin sodium is a type of anticoagulant. Also called Fragmin. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/dalteparin-sodium)
Mechanisms of Action: AT III Activator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Denmark | France | Germany | Hungary | India | Ireland | Italy | Korea | Morocco | New Zealand | Norway | Pakistan | Philippines | Portugal | Russia | Slovenia | South Africa | Spain | Taiwan | Tunisia | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Edema|Hypoalbuminemia|Kidney Diseases|Membranous Nephropathy|Nephrotic Syndrome|Proteinuria
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2019-001212-29 | P2 |
Active, not recruiting |
Proteinuria|Kidney Diseases|Hypoalbuminemia|Nephrotic Syndrome|Membranous Nephropathy|Edema |
None |